Financial Data and Key Metrics Changes - The company achieved revenue of $699 million in Q3 2025, resulting in 1% organic growth, with foreign exchange (FX) providing a modest tailwind of approximately 1% [24][26] - Adjusted operating margins were reported at 26.1%, slightly above expectations but down 220 basis points year-over-year due to tariffs, FX, and lower volume leverage [24][25] - Adjusted earnings per share (EPS) for the quarter was $1.18, exceeding the midpoint of guidance by $0.05 [26] Business Line Data and Key Metrics Changes - The signals software business grew 20% organically in the quarter, continuing to be a strong performer with an annual recurring revenue (ARR) of over 40% and a net retention rate of more than 110% [28] - The reproductive health business grew in the mid-single digits, with newborn screening growing in the high single digits [5][30] - The diagnostics segment generated $356 million in revenue, up 3% on a reported basis and 2% organically, with immunodiagnostics declining in the low single digits [29] Market Data and Key Metrics Changes - The Americas experienced low single-digit growth, Europe saw mid-single-digit growth, while Asia declined in the mid-single digits, with China specifically declining in the low teens [27] - The diagnostics business in China faced a decline of over 20%, significantly impacting overall performance [31][90] Company Strategy and Development Direction - The company is focusing on capital deployment through share repurchases, having repurchased approximately 2.3 million shares in Q3, totaling 12.5 million shares since the divestiture [8][26] - The company is optimistic about future performance, anticipating organic growth in the 2% to 4% range for the year, while raising adjusted EPS guidance to $4.90 to $5.00 [9][33] - Strategic partnerships, such as those with Genomics England and Sanofi, are expected to enhance product offerings and market presence [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding improving customer confidence and investment levels in the industry, despite current market stability [4][9] - The company is cautious in its assumptions until sustained improvements in broader industry demand trends are observed [10][18] - Management highlighted the importance of AI in driving productivity and innovation, with several new AI-based products launched [11][12] Other Important Information - The company reported a 6% reduction in scope one and two emissions in 2024 and a 77% employee satisfaction rate [17] - The company received a AAA rating from MSCI, indicating strong performance in ESG metrics [17] Q&A Session Summary Question: Insights on 2026 growth outlook - Management indicated a prudent assumption of 2% to 3% organic growth for 2026, with signs of increasing customer activity, particularly in the pharma sector [36][39] Question: Confidence in maintaining 28% operating margin - Management expressed confidence in achieving a 28% operating margin baseline for 2026, supported by ongoing actions and cost containment initiatives [41][42] Question: Performance of reagents in Q3 - Reagents were reported to be slightly below expectations, with modest declines noted, but underlying lab activity remains strong [78][79] Question: Impact of budget flush in Q4 - A modest seasonal increase in instrument sales is expected in Q4, with some improvement in customer activity levels noted [82] Question: Future of China diagnostics - Management expects continued headwinds in China diagnostics due to DRG impacts, but anticipates a return to low single-digit growth post-anniversary in Q2 2026 [90][92]

Financial Data and Key Metrics Changes - Revenue grew 5% in Q3 to $11.12 billion, with adjusted operating income increasing 9% to $2.59 billion [5][21] - Adjusted operating margin expanded by 100 basis points to 23.3% [5][21] - Adjusted EPS increased by 10% to $5.79 per share [5][20] Business Line Data and Key Metrics Changes - **Pharma and Biotech**: Mid-single-digit growth driven by bioproduction and analytical instruments [6] - **Academic and Government**: Revenue declined in low single digits, showing modest improvement [6] - **Industrial and Applied**: Revenue grew in mid-single digits, led by electron microscopy [6] - **Diagnostics and Healthcare**: Revenue growth improved but remained down low single digits, primarily due to conditions in China [6][25] Market Data and Key Metrics Changes - North America grew low single digits, Europe and Asia-Pacific grew mid-single digits, while China declined mid-single digits [21] - Total company adjusted gross margin was 41.9%, reflecting strong productivity [21] Company Strategy and Development Direction - The growth strategy focuses on high-impact innovation, trusted partner status, and a strong commercial engine [7][10] - Recent innovations include FDA-approved diagnostic tests and new electron microscopes [8][9] - Strategic collaborations, such as with OpenAI and AstraZeneca, aim to enhance product offerings and drive innovation [10][13] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating government policies and reshoring activities in the U.S. [33][34] - The company raised its full-year revenue guidance to $44.1 billion to $44.5 billion and adjusted EPS guidance to $22.60 to $22.86 [17][27] - Management remains optimistic about midterm and long-term growth prospects, expecting organic growth of 3% to 6% [54] Other Important Information - The company completed significant acquisitions, including a filtration and separation business and a sterile fill-finish site, enhancing its capabilities [14][15] - Share repurchases totaled $1 billion in Q3, bringing the total for the year to $3 billion [15][23] Q&A Session Summary Question: Market conditions and customer conversations - Management noted excitement among pharma and biotech customers regarding scientific breakthroughs and confidence in their pipelines [33][34] Question: Academic and government funding outlook - Management indicated a more stable funding environment is expected, despite the ongoing government shutdown adding some uncertainty [37][38] Question: Analytical instruments performance - Growth was driven by strong demand in electron microscopy and chromatography, with expectations for continued momentum [44] Question: Diagnostics in China - Management acknowledged weak conditions in China but noted a modest improvement relative to the previous quarter [45][46] Question: Biopharma demand from small biotech - There was positive momentum in clinical research and early activities in pharma services, indicating a potential reinvestment cycle [66][67] Question: Onshoring impact on capacity and volumes - Management discussed incremental demand from new facilities and equipment, but noted that overall drug volumes would remain stable [73][74]

Financial Data and Key Metrics Changes - Revenue grew 5% in Q3 2025 to $11.12 billion [6][26] - Adjusted operating income increased 9% to $2.59 billion [6][27] - Adjusted operating margin expanded by 100 basis points to 23.3% [6][27] - Adjusted EPS rose 10% to $5.79 per share [6][26] Business Line Data and Key Metrics Changes - **Pharma and Biotech**: Mid single-digit growth, driven by bioproduction and analytical instruments [6][7] - **Academic and Government**: Revenue declined in low single digits, showing slight improvement [7][52] - **Industrial and Applied**: Revenue grew in mid single digits, led by electron microscopy [8][32] - **Diagnostics and Healthcare**: Revenue growth improved but remained down low single digits, primarily due to conditions in China [8][64] Market Data and Key Metrics Changes - North America grew low single digits; Europe and Asia Pacific grew mid single digits; China declined mid single digits [26][27] - Total company adjusted gross margin was 41.9%, up 10 basis points year-over-year [28] Company Strategy and Development Direction - The growth strategy focuses on high-impact innovation, trusted partner status, and a strong commercial engine [9][13] - Collaborations with OpenAI aim to enhance product offerings and operational efficiency [14][15] - Strategic partnerships, such as with AstraZeneca, are intended to drive innovation in life sciences [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating government policies and the potential for reshoring in the pharma sector [46][49] - The company raised its full-year revenue guidance to $44.1 billion to $44.5 billion and adjusted EPS guidance to $22.6 to $22.86 [22][36] Other Important Information - The company repurchased $1 billion of shares in Q3, totaling $3 billion for the year [20][30] - The integration of recent acquisitions is progressing smoothly, with positive early feedback from customers [18][19] Q&A Session Summary Question: Market conditions and customer conversations - Management noted excitement around scientific breakthroughs and confidence in customer pipelines, with a focus on reshoring and navigating government policies [46][49] Question: Academic and government funding outlook - Management indicated a more stable funding environment is expected, despite the government shutdown adding some uncertainty [53][55] Question: Analytical instruments performance - Growth was driven by strong demand in electron microscopy and chromatography, with a positive outlook for the fourth quarter [60][62] Question: Diagnostics in China - Weak conditions were noted in China, but the company remains well-positioned for long-term growth despite current pressures [64][92] Question: 2026 growth outlook - Management remains confident in a 3% to 6% organic growth range, with expectations for improved market conditions over time [68][70] Question: Clinical research business trends - The clinical research business is performing well, with strong authorization rates and innovative approaches to improve drug development efficiency [78][80] Question: Demand from small and emerging biotech - There is a positive trend in demand from small biotech firms, supported by recent M&A activity in the sector [87]

Financial Data and Key Metrics Changes - Banner Corporation reported a net profit available to common shareholders of $53.5 million or $1.54 per diluted share for Q3 2025, an increase from $1.30 per share in Q3 2024 and $1.31 per share in Q2 2025 [4] - Core earnings for Q3 2025 were $67.8 million, up from $62.5 million in the prior quarter and $57.4 million in Q3 2024 [5] - Revenue from core operations was $169 million, compared to $163 million in the prior quarter and $154 million in Q3 2024 [6] - Return on average assets was 1.3% for Q3 2025, reflecting strong core performance [6] Business Line Data and Key Metrics Changes - Loans and core deposits both increased by 4% year-over-year, with core deposits representing 89% of total deposits [7] - Delinquent loans improved to 0.39% of total loans, down from 0.40% a year ago [9] - Adversely classified loans decreased by $16 million quarter-over-quarter, now at 1.49% of total loans [9] Market Data and Key Metrics Changes - The company maintained a strong core deposit base, which proved resilient and loyal [6] - The loan-to-deposit ratio ended the quarter at 84%, indicating ample capacity to add new clients [14] Company Strategy and Development Direction - The overarching goal is to provide a consistent and reliable source of commerce and capital through all economic cycles [4] - The company continues to focus on its supercommunity bank strategy, emphasizing client relationships and core funding [6] - Investments in technology and fraud-related systems are prioritized to enhance scalability and efficiency [47][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to manage through current market uncertainties due to a strong balance sheet and reputation [5] - The company anticipates solid loan growth in Q4, typically a strong quarter [12] - Management noted that the competitive landscape remains unchanged, with a focus on maintaining underwriting standards despite increased competition [41] Other Important Information - The company announced a 4% increase in the core dividend to $0.50 per common share [7] - Banner was recognized as one of America's 100 best banks and received various accolades for its performance and trustworthiness [8] Q&A Session Summary Question: Inquiry about margin and FHLB payoffs - Management indicated that FHLB advances were paid down halfway through the quarter, with expectations of flat funding costs despite Fed rate cuts [22][24] Question: Capital management and M&A interest - Management expressed confidence in continuing share repurchases and indicated readiness for potential M&A opportunities if they arise [26][28] Question: Deposit growth and pricing strategy - Management noted strong deposit growth driven by seasonal factors and indicated reductions in advertised CD rates following the Fed's rate cut [36] Question: Competitive landscape and loan originations - Management acknowledged a multifaceted decline in originations, attributing it to a strong prior quarter and muted reactions to rate cuts [41][42] Question: Strategic investments and technology - The company is investing heavily in technology to enhance scalability and efficiency, with a focus on fraud prevention and AI integration [47][48]

Core Viewpoint - Goldman Sachs held an investor meeting with HEI, highlighting that factors such as the aerospace aftermarket, market share growth, profit margins, and mergers and acquisitions will drive the company's stock price. Goldman maintains a "Buy" rating with a 12-month target price of $382, representing approximately a 19% upside from the recent closing price of $321.74 [1] Group 1: Capital Deployment - HEI is actively assessing merger and acquisition opportunities, focusing on core commercial aviation and defense businesses, with a net debt/EBITDA ratio of approximately 2.0x, providing ample capacity for acquisitions [2] Group 2: Aerospace Aftermarket - HEI has not observed a slowdown in the commercial aftermarket due to fleet aging, limited new aircraft supply, and sustained flight demand. The company anticipates that aftermarket growth will gradually normalize to about 2x GDP/ASK in the long term, rather than the current 14-15% level [3] Group 3: PMA (Parts Manufacturer Approval) - HEI sells PMA parts at a discount equivalent to 70% of OEM parts pricing, with potential discounts expanding to 50-60% as OEM prices rise. The PMA business is mature in commercial aviation but still in early stages in defense, with opportunities comparable to adding 1-2 large airline customers [4] Group 4: Wencor Integration - HEI continues to realize synergies from the acquisition of Wencor, finding that maintaining Wencor's relative independence allows for significant cross-selling and MRO synergies. This integration is driving higher FSG profit margins due to increased sales of PMA parts [5] Group 5: Profit Margins by Division - HEI reaffirms that FSG's EBIT margin is expected to be around 24% in the medium term, with potential for further upside. Recent margin improvements are attributed to higher defense business volume and PMA-friendly operations. In ETG, margins remain below pre-pandemic levels but are expected to expand in the future [6][7]

Core Insights - The company has focused on returning to basics, emphasizing accountability, agility, and innovation to improve business performance [1] - Progress has been made in three key priorities: top line growth through innovation and commercial excellence, operational performance, and effective capital deployment [2] Product Innovation - In the first half of the year, the company launched 126 products, which is nearly equivalent to the total of 128 products launched in all of 2023 [2]

Financial Data and Key Metrics Changes - The company achieved record sales, EBITDA, and EPS in fiscal 2025, with full-year EPS growth of 4% exceeding initial guidance [6][7] - Gross margins expanded nearly 50 basis points, surpassing 30% for the first time in history [6][7] - Free cash flow reached over $465 million, up 34% year-over-year, marking a new record [18][19] Business Line Data and Key Metrics Changes - The Engineered Solutions segment saw a 2% organic daily sales increase, marking the first year-over-year growth in seven quarters [10][11] - The Service Center segment experienced a 0.4% organic sales decline year-over-year, but showed improvement from a 1.6% decline in the previous quarter [37][38] - Overall, the Engineered Solutions segment's sales increased by 20.7% year-over-year, with acquisitions contributing significantly to this growth [40][41] Market Data and Key Metrics Changes - Year-over-year trends across the top 30 end markets remained mixed, with 15 markets showing positive sales growth [11][12] - Declines were noted in machinery, primary metals, utility and energy, aggregates, and chemicals, while demand was solid in technology, pulp and paper, and food and beverage sectors [12][13] - Orders in the Engineered Solutions segment increased by a high single-digit percentage year-over-year, indicating a positive trend [13] Company Strategy and Development Direction - The company is focused on accelerating growth while being mindful of ongoing trade and interest rate policy uncertainties [22][24] - There is an emphasis on increasing growth with local customers through ancillary products and comprehensive service solutions [26][28] - The company plans to remain active in M&A, with a developing pipeline for fiscal 2026 [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute amid evolving tariff backdrops and inflationary pressures [20][21] - The outlook for fiscal 2026 includes expectations for organic sales growth of 1% to 4% and EBITDA margins of 12.2% to 12.5% [45][46] - Management noted that recent U.S. trade agreements and tax reforms could positively impact business sentiment and capital investment [23][24] Other Important Information - The company repurchased 656,000 shares for $153 million and increased its quarterly dividend by 24% [19] - The Hydrodyne acquisition is expected to contribute positively to EPS and EBITDA, with synergy realization ahead of schedule [87][88] Q&A Session Summary Question: Hydrodyne's sequential sales growth and EBITDA contribution - Management indicated that the stronger margin performance was due to leverage from SG&A falling through to EBITDA and quicker realization of synergy benefits [53][54] Question: Break fix MRO market trends - Management noted positive trends in local accounts and indicated that there are signs of firming demand [56][57] Question: Pricing contributions in guidance - Management expects pricing contributions to be similar to the previous quarter, with potential increases as the year progresses [62] Question: Engineered Solutions segment growth drivers - Management highlighted growth in data centers and semiconductor manufacturing as key components of the technology vertical [63][64] Question: LIFO and AR provisioning impacts - Management clarified that the majority of AR provisioning impacts were skewed towards the Service Center segment, with expectations for normalization moving forward [75][76]

Financial Data and Key Metrics Changes - The company achieved record sales, EBITDA, and EPS in fiscal 2025, with full-year EPS growth of 4% exceeding initial guidance [6][7] - Gross margins expanded nearly 50 basis points, surpassing 30% for the first time in history [6][7] - Free cash flow reached over $465 million, up 34% year-over-year, marking a new record [17][18] Business Line Data and Key Metrics Changes - Engineered Solutions segment sales grew organically year-over-year for the first time in seven quarters, with a 2% organic daily sales increase [9][11] - Service Center segment trends improved, returning to positive organic growth in June, with average daily sales increasing 1.5% sequentially [11][37] - The Engineered Solutions segment saw a 20.7% increase in sales year-over-year, with acquisitions contributing 19.7 points to this increase [39] Market Data and Key Metrics Changes - Year-over-year trends across the top 30 end markets remained mixed, with 15 markets generating positive sales growth [11] - Declines were noted in machinery, primary metals, utility and energy, aggregates, and chemicals, while technology verticals showed solid demand [12][13] - Orders in the Engineered Solutions segment increased by a high single-digit percentage year-over-year, indicating a positive inflection [13] Company Strategy and Development Direction - The company is focused on accelerating growth while being mindful of ongoing trade and interest rate policy uncertainties [21][24] - There is an emphasis on increasing growth with local customers through greater sales of ancillary products and comprehensive service solutions [25][28] - The company plans to remain active in M&A, with a developing pipeline for fiscal 2026 [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute amid evolving tariff backdrops and inflationary pressures [19][20] - The outlook for fiscal 2026 includes expectations for organic sales growth of 1% to 4% and EBITDA margins of 12.2% to 12.5% [44][45] - Management noted that recent U.S. trade agreements and tax reforms could positively impact business sentiment and capital investment [22][24] Other Important Information - The company closed four acquisitions in fiscal 2025, including Hydrodyne, which contributed over 400 basis points of inorganic growth [18][39] - The company repurchased 656,000 shares for $153 million and increased its quarterly dividend by 24% [18] Q&A Session Summary Question: Hydrodyne's sequential sales growth and EBITDA performance - Management indicated that the improvement in Hydrodyne's performance was due to stronger margin performance and quicker realization of synergy benefits [52][53] Question: Break fix MRO market trends - Management noted positive trends in local accounts and national accounts, indicating potential firming in the market [54][55] Question: Pricing contributions to guidance - Management expects pricing contributions to remain similar in the first quarter, with potential increases as the year progresses [61][62] Question: Market softness in international operations - Management identified Canada as experiencing more softness due to tariff impacts, but noted improvements as the quarter progressed [97] Question: Hydrodyne's contribution to EBITDA - Hydrodyne contributed just over $7 million to EBITDA in Q4, aligning with initial expectations for the first twelve months [87][88]

Financial Data and Key Metrics Changes - Vinci Partners reported fee-related earnings of BRL65.2 million or BRL1.03 per share and adjusted distributable earnings of BRL75.8 million or BRL1.20 per share for Q2 2025, with a quarterly dividend of $0.15 per common share [4][10][40] - Total fee-related revenues increased by 85% year over year, reflecting strong strategic growth and positive inflows [36] - Adjusted distributable earnings totaled BRL75.8 million or $1.20 per share, representing a 30% increase year over year on a nominal basis [40] Business Line Data and Key Metrics Changes - The credit segment saw over BRL2 billion in new capital formation and AUM appreciation, indicating strong growth [17] - The private equity segment achieved over 20% year-over-year revenue growth and over 30% year-over-year EBITDA growth in 2025 [29] - The real asset segment completed significant transactions, including the full divestment of assets, contributing to deleveraging [11][30] Market Data and Key Metrics Changes - The local equity market in Brazil remains under-allocated, with equities representing just 8% of domestic portfolios, suggesting potential for reallocation as interest rates decline [14] - Latin America is experiencing a favorable macro landscape, with improving inflation expectations and easing policy, which is beneficial for alternative investments [16] - The Brazilian real appreciated by 5% against the U.S. dollar during the quarter, creating a currency headwind for AUM figures [35] Company Strategy and Development Direction - The company is focusing on sectors such as financial services, technology, and healthcare, while also monitoring opportunities in distressed companies and multinational carve-outs [13] - Vinci Partners aims to expand investments in renewable energy and is actively discussing utility-scale solar initiatives [19] - The firm is integrating teams and operations to maximize collaboration and enhance service delivery [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the fundraising environment, expecting continued strong inflows in the second half of the year [50][54] - The company anticipates a gradual reduction in financial income as capital is deployed from liquid funds to closed-end funds, with a significant impact expected starting in 2026 [46][70] - Management highlighted the potential for attractive entry points in the market due to suppressed valuations, particularly in Brazil [13] Other Important Information - Vinci Partners successfully closed its Infrastructure Climate Change Fund, raising close to BRL1 billion, primarily from international institutions [18] - The company inaugurated a new office in Sao Paulo, enhancing operational capabilities and collaboration [19][32] - An Investor Day is scheduled for October 7 at NASDAQ headquarters, providing an opportunity for deeper engagement with investors [20] Q&A Session Summary Question: Fundraising outlook for the second half - Management indicated that they expect to achieve double-digit growth in AUM on an FX-adjusted basis, with strong inflows continuing into the second half [50][54] Question: FRE margin expansion - Management expects FRE margins to migrate to the low 30s percent range by the second or third quarter of next year, driven by ongoing cost control initiatives and operational efficiencies [60][62] Question: PRE realizations timeline - Management anticipates that net income impacts from fund appreciation will begin in 2026, with distributable earnings expected to follow as funds start returning capital [70][72] Question: Impact of FX on management fees - Management confirmed that the flat management fees were primarily due to FX impacts, estimating that revenues would have grown by low to mid-single digits without the FX effect [78][80] Question: Credit portfolio and regional opportunities - Management highlighted growth in credit across Latin America, with significant fundraising opportunities in Brazil, Colombia, Peru, Mexico, and Chile [88][90]

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $440.8 million, a 12% decrease from $500.2 million a year ago [10] - Overall gross margin decreased by 2.7 percentage points to 28.4% [10] - Adjusted EBITDA for the quarter was $54 million, down from $64 million last year [10] - Net income for the quarter was $32.8 million, compared to $41.4 million a year ago [10] - GAAP earnings per share were $1.31, down from $1.65 a year ago [10] Business Line Data and Key Metrics Changes - **Performance Chemicals**: Revenues were $168.4 million, up 5% from $160.8 million last year, with operating income of $19.8 million, down 6% [11] - **Fuel Specialties**: Revenues were £170.3 million, down 4% from £176.9 million, but operating income increased by 10% to $36.9 million [12] - **Oilfield Services**: Revenues were $102.1 million, a 37% decrease from $162.5 million, with operating income down 76% to $4.1 million [13] Market Data and Key Metrics Changes - Performance Chemicals experienced a volume growth of 5% but faced a negative currency impact of 3% [11] - Fuel Specialties faced a 2% adverse price mix and a negative currency impact of 2% [12] - Oilfield Services saw no sales in Latin America, with potential recoveries delayed due to ongoing trade policy negotiations [9] Company Strategy and Development Direction - The company remains focused on delivering full-year operating income growth and margin improvement despite near-term challenges [7] - There is a commitment to security of supply, innovation, and world-class customer service [15] - The company is positioned to pursue M&A, dividend growth, organic investment, and buybacks due to a strong debt-free balance sheet [15] Management's Comments on Operating Environment and Future Outlook - Management noted that market conditions are extremely volatile, which may hinder the 2025 target for sequential improvement in operating income [7] - There is cautious optimism regarding customer behavior and inventory management in the Performance Chemicals segment [6][34] - The company expects to see some stabilization in oilfield services as fears around crude prices subside [61] Other Important Information - Cash from operating activities was $28.3 million before capital expenditures of $15.5 million [14] - The Board approved a 10% increase in the semiannual dividend to $0.84 per share [16] Q&A Session Summary Question: Impact of tariffs on input costs - Management indicated that they are monitoring the situation and have flexible supply chains to manage potential impacts [22][27] Question: Trends in Performance Chemicals - Management noted that customer caution and inventory management are influencing trends, with some signs of improvement [30][34] Question: Cost actions in oilfield business - The company is consolidating assets and focusing on efficiencies and cost reductions [39] Question: Earnings cadence for the rest of the year - Management expects Q2 to be similar to Q1, with slight improvements in Q3 and Q4 for oilfield services [41][45] Question: Fuel Specialties stability - Management expressed confidence in the stability of the Fuel Specialties business despite potential market fluctuations [52] Question: R&D efforts and customer collaborations - There has been no change in customer mindset regarding R&D collaborations, with some projects potentially accelerating [71][74] Question: Capital deployment and buyback strategy - The company plans to be opportunistic with buybacks and has the flexibility to pursue various capital allocation strategies [82][86]